Labcyte Inc., headquartered in Sunnyvale, California, and the Institute for Molecular Medicine Finland (FIMM) are collaborating to further the development of personalized medicine in cancer treatment. Labcyte acoustic liquid handling technology (see image) has already revolutionized small-molecule research. Now, FIMM, a European leader in advanced research for new cancer therapies, will apply the technology extensively in its personalized medicine programs. “FIMM’s groundbreaking use of acoustic liquid handling will demonstrate the technology’s role in genetic research,” said Mark Fischer-Colbrie, CEO of Labcyte. “FIMM has successfully used Labcyte acoustic liquid handling technology to generate better data and drive down costs in small-molecule screening for the past three years. This collaboration with such a well-regarded institute will facilitate breakthroughs in personalized medicine.” FIMM uses large sample sets with links to detailed patient records and genetic data to discover personalized treatment options at a faster pace. “We see an enormous potential in expanding our use of Labcyte acoustic dispensing technology to help discover specialized leukemia treatments,” said Professor Olli Kallioniemi, director of FIMM. “This research is based on high-throughput drug sensitivity and resistance testing of leukemic cells taken from patients. This new initiative will bring us closer to the clinic and closer to patients. Our aim is to find alternate treatment options for patients who simultaneously undergo treatment in the clinic,” said Professor Kallioniemi.Login Or Register To Read Full Story